Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Ioana Agache*, Jessica Beltran, Cezmi Akdis, Mubeccel Akdis, Carlos Canelo-Aybar, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández-Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. PapadopoulosAlberto Papi, Hae Sim Park, Luis Pérez de Llano, Margarita Posso, Claudio Rocha, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Yang Song, Corinna Steiner, Jurgen Schwarze, Pablo Alonso-Coello, Oscar Palomares, Marek Jutel

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Journal article

294 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma'. Together they form a unique fingerprint.

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science